3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
30
Glioblastoma
28
Breast Neoplasms
19
Lung Neoplasms
17
Carcinoma, Non-Small-Cell Lung
17
Oropharyngeal Neoplasms
14
Squamous Cell Carcinoma of Head and Neck
11
Sarcoma
10
Glioma
10
Esophageal Neoplasms
10
Brain Neoplasms
10
Urinary Bladder Neoplasms
9
Astrocytoma
9
Gliosarcoma
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Mouth Neoplasms
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Melanoma
6
Head and Neck Neoplasms
6
Carcinoma, Hepatocellular
6
Carcinoma
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Neoplasms
5
Laryngeal Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Carcinoma, Squamous Cell
5
Interventions
Cyclophosphamide
16
Mycophenolic Acid
13
Tacrolimus
10
fludarabine
9
ruxolitinib
8
Busulfan
7
fludarabine phosphate
6
Whole-Body Irradiation
6
Sirolimus
6
Melphalan
6
Methotrexate
5
Thiotepa
4
ibrutinib
3
Specimen Handling
3
Cyclosporine
3
Abatacept
3
Stem Cell Transplantation
2
Radiotherapy
2
Hematopoietic Stem Cell Transplantation
2
Clofarabine
2
Biopsy
2
vedolizumab
1
tildrakizumab
1
itacitinib
1
blinatumomab
1
belumosudil
1
axatilimab
1
Vorinostat
1
Therapeutics
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Graft vs Host Disease
×
Radiation
×
1 year
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled